Drug Trial Radar · NCT00777244
Efficacy of Adjuvant Mitotane Treatment (ADIUVO)
Last checked: Nov 20, 2026Latest source record: May 8, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
200
Planned (sponsor's estimate)
Start
Apr 2008
Primary completion
Dec 2018
Study completion Dec 2020
Sponsor
- Lead sponsor
- University of Turin, ItalyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 22, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study Rationale Adrenocortical carcinoma (ACC) is a very rare disease with a high risk of relapse after radical surgery. The efficacy of adjuvant mitotane treatment is suggested by a retrospective multicenter international study showing that postoperative mitotane treatment was associated with a significant reduction of the risk of relapse and death. However, these promising results need confirmation in a randomized prospective study. Caution should be adopted particularly in patients with low risk of disease relapse, in whom the benefit of therapy should be weighted against the side effects. Even if an adjuvant treatment seems justified in patients at high risk of relapse, a randomised prospective study is needed to assess whether such a treatment is efficacious in patients at low-intermediate risk. The purpose of the present study is to determine whether adjuvant mitotane treatment is effective in prolonging the disease free survival in patients with adrenocortical carcinoma at low-intermediate risk of progression who underwent radical resection
Conditions
- Adrenocortical Carcinoma
Interventions
MITOTANEDrug
mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance on day 2 to 3 g/day, on day 3 to 4.5 g/day, and on day 4 to 6 g/day. A dose of 6 g/day will be administered until first mitotane blood level is assessed. Further adjustment of dosage will be performed according to blood concentrations and tolerability.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease Free survivalTime frame: Till the last follow up
Locations
28 sites in 7 countries. Site status is shown where the registry gives one.
Medical Oncology Branch - Center for Cancer Research - National Cancer Institute
Bethesda, Maryland · Recruiting
Endocrine Oncology - University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan · Active not recruiting
Endocrinologie - Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, Canada · Recruiting
Endocrinologie - CHU Besançon Hôpital Jean Minjoz
Besançon, France · Recruiting
Endocrinologie - CHU Lyon Hôpital Pierre Wertheimer
Bron, France · Recruiting
Endocrinologie - Hôpital A. Michallon
La Tronche, France · Recruiting
Endocrinologie - Cochin, APHP
Paris, France · Recruiting
Endocrinologie - CHU Toulouse Hôpital Larrey
Toulouse, France · Recruiting
Endocrinologie - Institut de Cancérologie Gustave Roussy
Villejuif, France · Recruiting
University Hospital Campus Mitte Charitè, Berlin
Berlin, Germany · Recruiting
University Hospital of Dresden
Dresden, Germany · Recruiting
University Hospital of Düsseldorf
Düsseldorf, Germany · Not yet recruiting
Center for Endocrine Tumors - ENDOC
Hamburg, Germany · Recruiting
University Medicin Centre of Munchen
München, Germany · Recruiting
University Hospital Wuerzburg, Endocrinology
Würzburg, Germany · Recruiting
UO Oncologia Medica - AO Spedali Civili
Brescia, Italy · Recruiting
Università degli studi di Firenze
Florence, Italy · Not yet recruiting
Azienda Ospedaliera di Foggia
Foggia, Italy · Active not recruiting
Ospedale Cà Granda-Niguarda-Milano
Milan, Italy · Recruiting
Azienda Ospedaliera San Luigi
Orbassano, Italy · Recruiting
Department of Clinical and Biological Sciences, University of Turin, Internal Medicine 1
Orbassano, Italy · Recruiting
Azienda Ospedaliera Padova
Padova, Italy · Active not recruiting
Università degli studi di Palermo
Palermo, Italy · Not yet recruiting
Policlinico Universitario A. Gemelli
Roma, Italy · Active not recruiting
A.O.U. San Giovanni Battista - Molinette
Torino, Italy · Recruiting
A.O.Universitaria Arcispedale S.Anna Ferrara
Ferrara, Fe, Italy · Recruiting
Dept. of Internal Medicine Maxima Medisch Centrum
Eindhoven, Netherlands · Recruiting
Cancer Research UK Clinical Trials Unit (CRCTU) - School of Cancer Sciences - University of Birmingham
Birmingham, Edgbaston, United Kingdom · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.